Hemab Therapeutics Holdings, Inc. (COAG) Stock Forecast Oct. 19, 2026
Analysis updated on Oct. 19, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Hemab Therapeutics Holdings, Inc. (COAG) stock forecast summary
On Oct. 19, 2026, COAG is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 4016 stocks scored that day.
Hemab Therapeutics Holdings, Inc. is a small-cap company with a market capitalization of $1.50B. It ranks number 41 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its Current Ratio of 35.85x is the highest of the 59 peers that report one. Its D/E Ratio of 0.03x is the lowest of the 53 peers that report one.
For COAG, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 53.0%, measured on 44 forecast dates between 2026-05-21 and 2026-07-21 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -32.0%, measured on 87 forecast dates between 2026-05-21 and 2026-09-18. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-20 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, COAG included.
Follow COAG freeCOAG price chart and AI forecast
How COAG ranks among 4016 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Hemab Therapeutics Holdings, Inc. (COAG) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | COAG | Rank |
|---|---|---|
| Market Cap | $1.50B | 41/60 |
| P/B Ratio | 3.30x | 35/49 |
| Book Value/Share | $9.72 | – |
Financial Health
| Metric | COAG | Rank |
|---|---|---|
| Current Ratio | 35.85x | 1/59 |
| D/E Ratio | 0.03x | 53/53 |
| Financial Leverage | 1.03x | 52/52 |
| Working Capital | $451M | 29/59 |
Dividend & Shareholder Information
| Metric | COAG | Rank |
|---|---|---|
| Shares Outstanding | 47M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $464M | 99.2% of assets |
| Cash & Short-term Investments | $237M | 50.7% of assets |
| Total Liabilities | $14M | 2.9% of assets |
| Short-term Debt | $7M | 1.4% of assets |
COAG quarterly financials and insider trading
Hemab Therapeutics Holdings, Inc. (COAG) industry peers
Companies classified under the same SEC industry code as Hemab Therapeutics Holdings, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.50B |
| AMGN Amgen Inc | ▼ | $229.74B |
| GILD Gilead Sciences, Inc. | ▲ | $189.80B |
| MRNA Moderna, Inc. | ▲ | $90.58B |
| ARGX Argenx Se | ▼ | $51.09B |
| RVMD Revolution Medicines, Inc. | ▲ | $39.04B |
| BIIB Biogen Inc. | ▼ | $34.25B |
| BNTX Biontech Se | ▲ | $22.56B |
| EXEL Exelixis, Inc. | ▶ | $15.53B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.92B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.90B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| QGEN Qiagen N.V. | ▶ | $10.10B |
| RGEN Repligen Corp | ▲ | $9.96B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.48B |
| PCVX Vaxcyte, Inc. | ▲ | $9.48B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.99B |
| IBRX Immunitybio, Inc. | ▲ | $8.92B |
| TWST Twist Bioscience Corp | ▲ | $8.76B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.44B |
| KOD Kodiak Sciences Inc. | ▲ | $5.74B |
| IMVT Immunovant, Inc. | ▲ | $5.70B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.90B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.82B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.75B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.05B |
| DNLI Denali Therapeutics Inc. | ▼ | $2.88B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.50B |
| ADMA Adma Biologics, Inc. | ▼ | $2.48B |
| LIFE Atyr Pharma Inc | ▲ | $2.48B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.16B |
| VCEL Vericel Corp | ▶ | $2.07B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| ALVO Alvotech | ▲ | $1.80B |
| NVAX Novavax Inc | ▲ | $1.78B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.73B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.65B |
| MESO Mesoblast Ltd | ▶ | $1.55B |
| IMCR Immunocore Holdings Plc | ▶ | $1.54B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.28B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.04B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $945M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $909M |
| MGTX Meiragtx Holdings Plc | ▶ | $908M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $900M |
| SLBT Sl Science Holding Ltd | ▶ | $873M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $870M |
| PRME Prime Medicine, Inc. | ▲ | $695M |
| SANA Sana Biotechnology, Inc. | ▲ | $689M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $679M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $678M |
| AURA Aura Biosciences, Inc. | ▲ | $652M |
| SLDB Solid Biosciences Inc. | ▲ | $635M |
| CADL Candel Therapeutics, Inc. | ▲ | $628M |
| DBVT Dbv Technologies S.A. | ▶ | $531M |
| VALN Valneva Se | ▼ | $521M |
Where COAG sits on the market map
Hemab Therapeutics Holdings, Inc. (COAG) stock news
Loading...
Hemab Therapeutics Holdings, Inc. (COAG) stock forecast FAQ
What is the Hemab Therapeutics Holdings, Inc. (COAG) stock forecast?
On Oct. 19, 2026, COAG is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 4016 stocks scored that day.
How accurate are Hemab Therapeutics Holdings, Inc. stock predictions?
For COAG, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 53.0%, measured on 44 forecast dates between 2026-05-21 and 2026-07-21 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -32.0%, measured on 87 forecast dates between 2026-05-21 and 2026-09-18. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Hemab Therapeutics Holdings, Inc. forecasts updated?
Hemab Therapeutics Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 19, 2026.
Which companies are Hemab Therapeutics Holdings, Inc.'s industry peers?
60 issuers in our coverage, COAG included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.